Puerarin Enhances the Anti-Tumor Effect of Cisplatin on Drug-Resistant A549 Cancer in vivo and in vitro Through Activation of the Wnt Signaling Pathway

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Mokhles S, Nuyttens JJ, Maat AP, et al. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis. Ann Surg Oncol. 2015;22:316–323. doi:10.1245/s10434-014-3860-x24962941
   PubMed Web of Science ®Google Scholar
• Capelletto E, Novello S, Scagliotti GV. First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. Future Oncol. 2014;10:1081–1093. doi:10.2217/fon.13.24724941991
   PubMed Web of Science ®Google Scholar
• MacDonagh L, Gray SG, Breen E, et al. Lung cancer stem cells: the root of resistance. CA Cancer Lett. 2016;372:147–156. doi:10.1016/j.canlet.2016.01.012
   PubMed Web of Science ®Google Scholar
• Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res. 2014;28:961–975. doi:10.1002/ptr.508324339367
   PubMed Web of Science ®Google Scholar
• Ye G, Kan S, Chen J, Lu X. Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway. Oncol Lett. 2019;17:195–200. doi:10.3892/ol.2018.960030655755
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao W, Wang W, Lin S, Yang L. Puerarin suppresses LPS-induced breast cancer cell migration, invasion and adhesion by blockage NF-κB and Erk pathway. Biomed Pharmacother. 2017;92:429–436. doi:10.1016/j.biopha.2017.05.10228558356
   PubMed Web of Science ®Google Scholar
• Zhang XL, Wang BB, Mo JS. Puerarin 6″-O-xyloside possesses significant antitumor activities on colon cancer through inducing apoptosis. Oncol Lett. 2018;16:5557–5564. doi:10.3892/ol.2018.936430344709
   PubMed Web of Science ®Google Scholar
• Hu Y, Li X, Lin L, Liang S, Yan J. Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis. Oncol Rep. 2018;39:1731–1738. doi:10.3892/or.2018.623429393465
   PubMed Web of Science ®Google Scholar
• Chen T, Chen H, Wang Y, Zhang J. In vitro and in vivo antitumour activities of puerarin 6″-O-xyloside on human lung carcinoma A549 cell line via the induction of the mitochondria-mediated apoptosis pathway. Pharm Biol. 2016;54:1793–1799. doi:10.3109/13880209.2015.112798026730946
   PubMed Web of Science ®Google Scholar
• Anukunwithaya T, Poo P, Hunsakunachai N, Rodsiri R, Malaivijitnond S, Khemawoot P. Absolute oral bioavailability and disposition kinetics of puerarin in female rats. BMC Pharmacol Toxicol. 2018;25:25. doi:10.1186/s40360-018-0216-3
   Web of Science ®Google Scholar
• Tan WL, Jain A, Takano A, et al. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016;17:e347–e362. doi:10.1016/S1470-2045(16)30123-127511159
   PubMed Web of Science ®Google Scholar
• Wakelee H, Kelly K, Edelman MJ. 50 years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2014;34:177–189. doi:10.14694/EdBook_AM.2014.34.177
   Google Scholar
• Hirsch HR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311. doi:10.1016/S0140-6736(16)30958-827574741
   PubMed Web of Science ®Google Scholar
• Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11:805–823. doi:10.1002/1878-0261.1209528599100
   PubMed Web of Science ®Google Scholar
• Tian T, Sun J, Wang J, Liu Y, Liu H. Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells. Oncol Lett. 2018;16:6133–6139. doi:10.3892/ol.2018.934430344755
   PubMed Web of Science ®Google Scholar
• Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70. doi:10.1186/s12943-019-0994-230927908
   PubMed Web of Science ®Google Scholar
• Yochum ZA, Cades J, Wang H, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019;38:656–670. doi:10.1038/s41388-018-0482-y30171258
   PubMed Web of Science ®Google Scholar
• Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting. Front Oncol. 2018;8:267. doi:10.3389/fonc.2018.0026730087852
   PubMed Web of Science ®Google Scholar
• Yang F, Qin Z, Shao C, et al. Association between VEGF gene polymorphisms and the susceptibility to lung cancer: an updated meta-analysis. Biomed Res Int. 2018;2018:9271215.30013987
   PubMed Web of Science ®Google Scholar
• Kretzschmar K, Clevers H. Wnt/β-catenin signaling in adult mammalian epithelial stem cells. Dev Biol. 2017;428:273–282. doi:10.1016/j.ydbio.2017.05.01528526587
   PubMed Web of Science ®Google Scholar
• Hafeez BB, Ganju A, Sikander M, et al. Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic β-catenin signaling and EMT progression. Mol Cancer Ther. 2017;16:2267–2280. doi:10.1158/1535-7163.MCT-17-015728615299
   PubMed Web of Science ®Google Scholar
• Yu W, Li L, Zheng F, et al. β-catenin cooperates with CREB binding protein to promote the growth of tumor cells. Cell Physiol Biochem. 2017;44:467–478. doi:10.1159/00048501329141249
   PubMedGoogle Scholar
• Chen Z, He J, Xing X, et al. Mn12Ac inhibits the migration, invasion and epithelial-mesenchymal transition of lung cancer cells by downregulating the Wnt/β-catenin and PI3K/AKT signaling pathways. Oncol Lett. 2018;16:3943–3948. doi:10.3892/ol.2018.913630128012
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang B, Sun L, et al. MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway. Cell Biochem Funct. 2018;36:194–202. doi:10.1002/cbf.333129653464
   PubMed Web of Science ®Google Scholar
• Che J, Yue D, Zhang B, et al. Claudin-3 inhibits lung squamous cell carcinoma cell epithelial-mesenchymal transition and invasion via suppression of the Wnt/β-catenin signaling pathway. Int J Med Sci. 2018;15:339–351. doi:10.7150/ijms.2292729511369
   PubMed Web of Science ®Google Scholar
• Zhang K, Wang J, Yang L, et al. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer. Mol Cancer. 2018;17:153. doi:10.1186/s12943-018-0896-830348169
   PubMed Web of Science ®Google Scholar
• Han F, Liu W-B, Shi X-Y, et al. SOX30 inhibits tumor metastasis through attenuating Wnt-signaling via transcriptional and post translational regulation of β-catenin in lung cancer. EBioMedicine. 2018;31:253–266. doi:10.1016/j.ebiom.2018.04.02629739711
   PubMed Web of Science ®Google Scholar
• Huang GR, Wei SJ, Huang YQ, Xing W, Wang LY, Liang LL. Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/β-catenin signalling pathway. World J Gastroenterol. 2018;24:4178–4185. doi:10.3748/wjg.v24.i36.417830271082
   PubMed Web of Science ®Google Scholar
• Bacanlı M, Başaran AA, Başaran N. The antioxidant, cytotoxic, and antigenotoxic effects of galangin, puerarin, and ursolic acid in mammalian cells. Drug Chem Toxicol. 2017;40:256–262. doi:10.1080/01480545.2016.120968027461151
   PubMed Web of Science ®Google Scholar
• Ma X, Yan L, Zhu Q, Shao F. Puerarin attenuates cisplatin-induced rat nephrotoxicity: the involvement of TLR4/NF-κB signaling pathway. PLoS One. 2017;12:e0171612. doi:10.1371/journal.pone.017161228182789
   PubMed Web of Science ®Google Scholar